Literature DB >> 24419524

Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT.

T G Ketterl1, M Flesher2, R Shanley3, W Miller2.   

Abstract

Following hematopoietic SCT (HSCT) for non-malignant disorders (NMDs) variable donor chimerism among lympho-hematopoietic lines may be observed. We retrospectively evaluated early post-HSCT, lineage-sorted (CD3+ and CD15+) peripheral blood leukocyte chimerism data to characterize patterns and assess for association with long-term CD15+ engraftment. 'Early' was defined as the first value obtained between days +14 and +42, 'late' as the last recorded value after day +90. 'High' donor chimerism was defined as 80% on either fraction at all time-points. Patients were classified into four subgroups with respect to early CD3+/CD15+ chimerism patterns (high/low) then analyzed for long-term CD15+ chimerism status. A total of 135 transplants were evaluable, with all three time-points available in 97. Underlying disease, graft source, patient age and conditioning intensity varied. 'Split' early chimerism (discordant high/low CD3+/CD15+ status) was common. Multivariable analysis revealed strong association between conditioning regimen and primary disease on early CD3+/CD15+ chimerism patterns and a dominant predictive effect of early CD15+ chimerism on long-term CD15+ donor engraftment (observed at median day +365). These data may guide real-time clinician decisions (restraint vs intervention, when available) when faced with unfavorable or unusual early lympho-hematopoietic chimerism patterns following HSCT for NMD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419524     DOI: 10.1038/bmt.2013.207

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

Review 1.  Hematopoietic cell therapy for metabolic disease.

Authors:  Paul J Orchard; Bruce R Blazar; John Wagner; Lawrence Charnas; William Krivit; Jakub Tolar
Journal:  J Pediatr       Date:  2007-10       Impact factor: 4.406

Review 2.  The clinical outcome of Hurler syndrome after stem cell transplantation.

Authors:  Mieke Aldenhoven; Jaap Jan Boelens; Tom J de Koning
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

3.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

Review 4.  Hematopoietic stem cell transplantation for thalassemia.

Authors:  Javid Gaziev; Guido Lucarelli
Journal:  Curr Stem Cell Res Ther       Date:  2011-06       Impact factor: 3.828

5.  Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.

Authors:  Rebecca A Marsh; Gretchen Vaughn; Mi-Ok Kim; Dandan Li; Sonata Jodele; Sarita Joshi; Parinda A Mehta; Stella M Davies; Michael B Jordan; Jack J Bleesing; Alexandra H Filipovich
Journal:  Blood       Date:  2010-09-20       Impact factor: 22.113

Review 6.  Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.

Authors:  Franco Locatelli; Daria Pagliara
Journal:  Pediatr Blood Cancer       Date:  2012-04-27       Impact factor: 3.167

7.  Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report.

Authors:  Weston P Miller; Steven M Rothman; David Nascene; Teresa Kivisto; Todd E DeFor; Richard S Ziegler; Julie Eisengart; Kara Leiser; Gerald Raymond; Troy C Lund; Jakub Tolar; Paul J Orchard
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

Review 8.  Bone marrow transplantation for inherited bone marrow failure syndromes.

Authors:  Parinda Mehta; Franco Locatelli; Jan Stary; Franklin O Smith
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

Review 9.  Hematopoietic cell transplantation for correction of primary immunodeficiencies.

Authors:  Ah Filipovich
Journal:  Bone Marrow Transplant       Date:  2008-08       Impact factor: 5.483

10.  Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.

Authors:  Marco Andreani; Manuela Testi; Javid Gaziev; Rossella Condello; Andrea Bontadini; Pier Luigi Tazzari; Francesca Ricci; Lidia De Felice; Francesca Agostini; Daniela Fraboni; Giuliana Ferrari; Mariarosa Battarra; Maria Troiano; Pietro Sodani; Guido Lucarelli
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

View more
  2 in total

1.  Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.

Authors:  Mark Parta; Corin Kelly; Nana Kwatemaa; Narda Theobald; Diane Hilligoss; Jing Qin; Douglas B Kuhns; Christa Zerbe; Steven M Holland; Harry Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2017-07-28       Impact factor: 8.317

2.  Impact of Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Bone Transplantation on the Treatment Outcome of Non-Malignant Disease.

Authors:  Young Bae Choi; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Hee-Jin Kim; Keon Hee Yoo
Journal:  J Korean Med Sci       Date:  2019-01-29       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.